Wang, Lufan
Langlais, Crystal
Kenfield, Stacey A.
Van Loon, Katherine
Laffan, Angela
Atreya, Chloe E.
Chan, June M.
Zhang, Li
Allen, Isabel E.
Miaskowski, Christine
Fukuoka, Yoshimi
Meyerhardt, Jeffrey A.
Venook, Alan P.
Van Blarigan, Erin L.
Funding for this research was provided by:
National Institutes of Health (K07CA197077)
Article History
Received: 13 September 2022
Accepted: 29 January 2023
First Online: 10 February 2023
Declarations
:
: Approval was obtained from the ethics committee of the UCSF Institutional Review Board. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication. Any patient identifying information is not included in this manuscript.
: CSL received funding from the National Cancer Institute of the National Institutes of Health (F31CA247093) and the University of California Prostate Cancer Program Pilot Award, was a consultant at Bohn Epidemiology, LLC during the 3-year period surrounding this work, and is currently employed as an Epidemiologist at IQVIA, unrelated to the current study. SAK is a consultant and board member for Fellow Health Inc., unrelated to the current study. JAM has served as an advisor/consultant to Merck Pharmaceutical and COTA Healthcare. No other potential conflicts of interest were reported.